Gadopentetate dimeglumine (Magnevist)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiovascular Abnormalities
Conditions
Cardiovascular Abnormalities
Trial Timeline
Dec 1, 2003 → Oct 1, 2004
NCT ID
NCT00310609About Gadopentetate dimeglumine (Magnevist)
Gadopentetate dimeglumine (Magnevist) is a phase 3 stage product being developed by Bayer for Cardiovascular Abnormalities. The current trial status is completed. This product is registered under clinical trial identifier NCT00310609. Target conditions include Cardiovascular Abnormalities.
What happened to similar drugs?
9 of 20 similar drugs in Cardiovascular Abnormalities were approved
Approved (9) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00310557 | Phase 3 | Completed |
| NCT00310609 | Phase 3 | Completed |
| NCT00309075 | Phase 3 | Completed |
Competing Products
20 competing products in Cardiovascular Abnormalities